Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 Jul 9:19:100818.
doi: 10.1016/j.ajoc.2020.100818. eCollection 2020 Sep.

Trichiasis and dry eye syndrome in two patients on novel fibroblast growth factor receptor inhibitor therapies

Kyle B Vinson  1 , Wesley M Gillette  1 , Catherine F Baston  2 , Alan B Leahey  2
Affiliations
Case Reports

Trichiasis and dry eye syndrome in two patients on novel fibroblast growth factor receptor inhibitor therapies

Kyle B Vinson et al. Am J Ophthalmol Case Rep. .

Abstract

Purpose: Present two patients on two different novel FGFR inhibitors who developed trichiasis with dry eye syndrome.

Observations: Two patients developed trichiasis and dry eye following FGFR inhibitor therapy. Treatments included artificial tears, lifitegrast or cyclosporine, and epilation as needed. One patient discontinued treatment with AZD4547 due to the severity of the ocular adverse effects.

Conclusions and importance: Trichiasis has not yet been reported in patients receiving AZD4547 or INCB054828 treatments and may represent a rare adverse effect of these drugs. Continued research is necessary to determine whether there is a definite link between these FGFR inhibitors and the development of trichiasis.

Keywords: AZD4547; Fibroblast growth factor receptor (FGFR) inhibitor; INCB054828; Pemigatinib; Trichiasis; dry eye.

PubMed Disclaimer

Conflict of interest statement

The following authors have no financial disclosures: KBV, WMG, CFB, ABL.

Figures

Fig. 1
Fig. 1
Case 2, left upper lid demonstrating trichiasis with coiled and wire-like lashes.
See this image and copyright information in PMC

References

    1. Huynh H., Ngo V.C., Fargnoli J. Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma. Clin Canc Res. 2008;14(19):6146–6153. doi: 10.1158/1078-0432.CCR-08-0509. - DOI - PubMed
    1. Andre F., Ranson M., Dean E. Abstract LB-145: results of a phase I study of AZD4547, an inhibitor of fibroblast growth factor receptor (FGFR), in patients with advanced solid tumors. Canc Res. 2013;73(8 suppl ment) doi: 10.1158/1538-7445.AM2013-LB-145. LB-145-LB-145. - DOI
    1. Arkenau H.-T., Saggese M., Hollebecque A. A phase 1 expansion cohort of the fibroblast growth factor receptor (FGFR) inhibitor AZD4547 in patients (pts) with advanced gastric (GC) and gastroesophageal (GOJ) cancer. ASCO Meet Abstr. 2014;32(15_suppl):2620. doi: 10.1200/jco.2014.32.15_suppl.2620. - DOI
    1. Saleh M., Gutierrez M.E., Subbiah V. Abstract CT111: preliminary results from a phase 1/2 study of INCB054828, a highly selective fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced malignancies. Canc Res. 2017;77(13 suppl ment) doi: 10.1158/1538-7445.AM2017-CT111. CT111-CT111. - DOI
    1. Renouf D.J., Velazquez-Martin J.P., Simpson R., Siu L.L., Bedard P.L. Ocular toxicity of targeted therapies. J Clin Oncol. 2012;30(26):3277–3286. doi: 10.1200/JCO.2011.41.5851. - DOI - PubMed

Publication types

LinkOut - more resources